BioInvent International
LUND, SWEDEN / ACCESSWIRE / October 25, 2021 / BioInvent International (STO:BINV)
- Holds extensive expertise in surgical oncology, immunotherapy, and drug development
- Will provide valuable input as BioInvent further expands clinical pipeline of cancer drugs
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of the renowned immunotherapy expert Alexander Eggermont MD, PhD, as a member of its Scientific Advisory Board.
Prof. Eggermont is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development. He currently holds roles as Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology and Professor of Clinical & Translational Immunotherapy at the University Medical Center Utrecht, the Netherlands. In Germany he is Coordinator at the Comprehensive Cancer Center Program for Deutsche KrebsHilfe and Strategic Advisor at the German Cancer Research Institute (DKFZ), Heidelberg.
"I am delighted to welcome Alexander Eggermont to BioInvent. His extensive experience in immunotherapy and cancer drug development will further strengthen our Scientific Advisory Board and will be invaluable as BioInvent further expands its clinical pipeline of first-in-class immuno-modulatory antibodies for cancer therapies, which currently includes three drug candidates in four ongoing clinical programs," said Martin Welschof, CEO of BioInvent.
Prof. Eggermont was previously Director General of Gustave Roussy Comprehensive Cancer Center, Villejuif, France and Professor of Oncology (Classe Exceptionelle) at Paris-Saclay University, France. Professor of Surgical Oncology and Endowed Professor of International Networking in Cancer Research at Erasmus University MC, Rotterdam, the Netherlands. He holds a PhD in tumor immunology from Erasmus University and is a Fellow of the National Institutes of Health's National Cancer Institute (NIH-NCI). He held international positions as President of the European Academy of Cancer Sciences; President of ECCO and President of EORTC.
The other valued members of the BioInvent Scientific Advisory Board are Mark Cragg, Professor of Experimental Cancer Research within Medicine at the University of Southampton, Stephen Beers, Professor of Immunology and Immunotherapy in the Faculty of Medicine at the University of Southampton, Falk Nimmerjahn, Professor in experimental immunology and immune therapy at the Friedrich-Alexander University Erlangen-Nürnberg, Rienk Offringa, Professor at the German Cancer Research Center and Alexander Rudensky, Chair of the Immunology Program at Sloan Kettering Institute.
The main task of the Scientific Advisory Board is to provide BioInvent with valuable input in its effort to develop new antibody treatments for various forms of cancer diseases. The Scientific Advisory Board brings together a wealth of knowledge in the areas of antibody and cancer immunobiology relevant to anti-cancer drug development.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com
For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0) 46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0) 46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/669466/BioInvent-Appoints-Immunotherapy-Expert-Alexander-Eggermont-to-Scientific-Advisory-Board
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AM Positions for Next Phase of Global Growth: Kelly McAndrew to Chairman; Dave Watrous to CEO27.1.2026 07:00:00 CET | Press release
AUSTIN, TX / ACCESS Newswire / January 27, 2026 / For over 21 years, Kelly McAndrew has served as Chief Executive Officer (CEO), playing a pivotal role in shaping AM Technical Solutions (AM) culture and strategic direction, enabling exceptional results. Kelly now transitions into the role of Chairman of the Board. As Chairman, Kelly will focus on investments and partnerships to further enhance the company's solution offerings. Dave Watrous will succeed Kelly as Chief Executive Officer. AM has worked closely with Dave for more than six years in the roles of customer and partner. His faith, integrity, leadership qualities, and strong industry expertise make him the ideal choice for this role. With a distinguished 30-year career in High-Technology industries, Dave brings extensive capabilities in delivering multi-billion-dollar Engineering, Procurement, Construction, Commissioning, and Validation projects worldwide. As CEO, Dave will focus on leading growth, accelerating opportunities, en
Richter Extends Its Support to Africa - The First Year of the House of Hope in Bamako in Numbers26.1.2026 14:00:00 CET | Press release
The First Year of the House of Hope in Bamako in Numbers BUDAPEST, HU / ACCESS Newswire / January 26, 2026 / Nearly one year has passed since the House of Hope centre, established by Richter Gedeon Plc., began providing shelter and comprehensive support to women in Bamako. During this period, almost 120 women and girls have benefited from healthcare, legal aid and education. Interest in the centre remains strong, with new women continuously joining the programme. In the coming years, the initiative aims to reach several hundred vulnerable women across different regions of Mali. Why Was the House of Hope Established? The centre was created through the collaboration of Richter Gedeon Plc. (Richter), the Hungary-based Close to Africa Foundation, and the local Sini Sanuman Foundation. Its mission is to provide safety and professional support to women fleeing violence and abuse through gynaecological care, psychological and legal counselling, and educational programmes. The building was des
TIS Appoints New CEO to Accelerate Global Growth26.1.2026 13:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / January 26, 2026 / Treasury Intelligence Solutions (TIS), a leading cloud-based platform for payments and cash management, today announced Zlatko Vucetic as the new Chief Executive Officer (CEO) effective from February 1, 2026. This move comes as a pivotal step in advancing the company's long-term vision and global growth strategy in cloud-native cash management, liquidity, and payment solutions. As an experienced CEO, Zlatko brings a strong track record in scaling software companies across Europe, Asia, and the U.S., combined with deep expertise in driving innovation and accelerating growth in competitive markets. Zlatko will lead TIS in its journey to be a market leader in payment and liquidity management across Europe and North America. After five successful years as CEO, Erik Masing will transition into the role of Vice Chair of the Board, where he will continue to provide strategic guidance and support. Under Erik's leadership, TIS achieved significa
Datavault AI to Support Establishment of International Research Center Focused on Real-World Asset Digitization in Taiwan26.1.2026 12:00:00 CET | Press release
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 26, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real‑world asset ("RWA") tokenization technologies, today announced the execution of a memorandum of understanding with St. John's University in Taipei to support the establishment of the RWA International Research Center (the "Center"). The Center will serve as a core platform for promoting inter-university alliances and international industry-academia collaboration, as well as for advancing the study of real-world asset tokenization frameworks, regulatory technology, and applied financial innovation. The Center is scheduled to be inaugurated on St. John's University's campus on January 26, 2026. The collaboration is expected to be structured as an academic and applied research initiative focused on advancing standards, education, and cross-disciplinary collaboration to support the resp
Masar Destination Achieves LEED for Communities Gold Certification23.1.2026 21:35:00 CET | Press release
Affirming its Commitment to Sustainability MAKKAH, SAUDI ARABIA / ACCESS Newswire / January 23, 2026 / Masar: a landmark urban development in the heart of Makkah, owned, developed, and operated by Umm Al Qura for Development & Construction Company, has been awarded LEED Gold certification under the LEED for Communities rating system, one of the highest international certifications in sustainability and the built environment. This achievement recognizes Masar's adoption of an integrated approach that places people and the environment at the heart of its design and planning processes. This accomplishment reflects the company's commitment to developing sustainable urban communities in line with global best practices. By balancing quality of life, resource efficiency, and environmental protection, it paves the way for long-term positive impact and a more sustainable future. Commenting on the achievement, Mr. Yasser Abuateek, Chief Executive Officer of Umm Al Qura for Development & Construc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom